Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Approved to Launch Humira Biosimilar in China

publication date: Sep 3, 2020

Suzhou Innovent Bio was approved by China's NMPA to market Sulinno® (adalimumab), a Humira® biosimilar. Sulinno, a recombinant human anti-TNF-α monoclonal antibody, is indicated to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Sulinno is Innovent's third monoclonal antibody drug to hit the market, joining Tyvyt® , the company's PD-1 mAb indicated for Hodgkin's lymphoma, and Byvasda® , an Avastin biosimilar for NSCLC and colorectal cancer. Innovent noted that Sulinno is the company's first product approved for a non-oncology indication. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China